BANTIA, SHANTA,BREITFELD, PHILIP,BABU, YARLAGADDA S
申请号：
NZ58641608
公开号：
NZ586416A
申请日:
2008.12.10
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed is the use of (a) Forodesine (7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl]-1,5-dihydropyrrolo[2,3-e]pyrimidin-4-one or Immucillin H), (b) Bendamustine (4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid) and optionally (c) an anti-CD20 agent, in the manufacture of a medicament for treating a hematologic cancer in a subject in need thereof, wherein the medicament is formulated for separate, sequential or simultaneous administration of (a), (b) and (c). An example of an anti - CD20 agent is Rituximab which is an antibody. Examples of hematologic cancers are non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and acute lymphoblastic leukaemia. Also disclosed is a pharmaceutical composition comprising Forodesine, Bendamustine and an optional anti-CD20 agent.
